gsk2256098
Small moleculeexperimental
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 6, 2009 (NCT00996671)
Timeline
Indications
Mechanism of action
- Focal adhesion kinase 1INHIBITOR
PTK2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CONC(=O)c1ccccc1Nc1cc(Nc2cc(C)nn2C(C)C)ncc1Cl- Mol. weight
- 414.9 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4742157 ↗
- ChEMBLCHEMBL3544967 ↗
Also known as
- gsk2256098
- gsk2256098
- gsk2256098
- gsk-2256098
- gsk-2256098
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02428270 | Phase 2 | Apr 1, 2016 | GlaxoSmithKline, University of Toronto |
| NCT02551653 | Phase 1 | Nov 1, 2015 | GlaxoSmithKline |
| NCT02523014 | Phase 2 | Aug 1, 2015 | Brain Science Foundation, Genentech, GlaxoSmithKline, Harvard University, National Cancer Institute (NCI) |
| NCT01938443 | Phase 1 | Nov 18, 2013 | GlaxoSmithKline |
| NCT01138033 | Phase 1 | Jul 27, 2010 | GlaxoSmithKline |
| NCT00996671 | Phase 1 | Nov 6, 2009 | GlaxoSmithKline |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 6 | 4 | 2 | 2009 |
| Brain Science Foundation | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Genentech | For profit | 1 | 0 | 1 | 2015 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2015 |
| University of Toronto | Academic/Hospital | 1 | 1 | 1 | 2016 |
6 organizations
Page 1 / 1